Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Antiviral therapy for HBV may play an important role here, as a large observation study from
Taiwan reported that the use of nucleos(t)ide analogues (NUC) was associated with 33%
reduction in HCC recurrence. In the first randomized controlled trial evaluating the use of
NUC after surgical resection for HCC, NUC therapy was associated with better 2-year overall
(94% vs. 62%) and recurrence-free (56% vs. 20%) survival. However, patients with active liver
disease should be treated regardless of their impact on HCC recurrence (patients with high
serum HBV DNA and abnormal ALT). What is less clear is that whether patients with low level
HBV DNA, and normal serum ALT levels should be treated to reduce HCC recurrence.
In this trial, we will investigate to determine the efficacy of the treatment with Tenofovir
disoproxil fumarate (Viread(R)) as measured by the cumulative incidence rate of
hepatocellular carcinoma (HCC) at 3 year after curative treatment with radiofrequency
ablation (RFA) or surgical resection (SR) in chronic hepatitis B virus (HBV) infected
patients with low viral load.